India's GLP-1 market shifted in March 2026 when the semaglutide patent expired. Branded Ozempic and Wegovy lost local exclusivity within weeks. Biocon, Dr. Reddy's, and other domestic manufacturers brought licensed generics to retail at prices a fraction of branded Western pricing.
The price gap has been steep enough to drive both clinical and self-medication demand. Indian outlets including The Week have quoted physicians warning about unsupervised self-use through unapproved online channels — pancreatitis, thyroid risk, and incorrect dose titration. CDSCO has been tightening import and prescription oversight. The grey market for compounded and unapproved peptides remains large.
Stories here cover Indian regulatory action, generic launches, telehealth and pharmacy distribution, and the consumer-safety reporting that has followed.
Merck (MSD) announced Friday July 24, 2026 seven voluntary, royalty-free, non-exclusive licensing agreements with generic drug manufacturers covering the investigational once-monthly oral HIV prevention pill MK-8527 (alimatravir). The licensees are Aspen Pharmacare (South Africa), Quality Chemical Industries (Uganda), and UCL Kenya in sub-Saharan Africa, plus Aurobindo, Cipla, Emcure, and Viatris in India. The territorial scope covers 129 low- and middle-income countries including every African nation. Alimatravir is an investigational late-stage once-monthly long-acting oral medicine for HIV-1 prevention, currently in Phase 3 development. Phase 3 topline results are not expected until late 2027. Alimatravir is designed to provide one month of protection from HIV-1 starting within one hour after dosing. Coverage frames the licensing structure as one of the broadest generic-access pre-approval commitments Merck has undertaken for an HIV asset. The announcement follows the April 7 STAT reporting that Merck's experimental HIV prevention pill could be made for less than $5 a year at manufacturing cost. Merck plans to file for regulatory approval in 2027-2028 with market launch dependent on Phase 3 outcome.
The Week reports that India's GLP-1 market is surging following semaglutide patent expiry in March, with doctors warning that self-medication — particularly through unapproved online channels — poses serious risks including pancreatitis and thyroid complications. Experts emphasize the need for clinical oversight and proper dose titration.
CNBC reports Eli Lilly's Indian GLP-1 market share fell from 61% to 56% in March as 26 generic semaglutide brands from 13 companies entered the market following patent expiry. Novo Nordisk held steady at 25% after slashing Ozempic prices 38% and Wegovy prices 48%, while Lilly's Mounjaro remains priced 10x above the cheapest generics.
Tirzepatide (Mounjaro) Indian sales fell to ₹114 crore in March from ₹135 crore in February, while semaglutide sales rose to ₹59 crore. Semaglutide's GLP-1 segment share jumped to 33% from 25% as dozens of generics flood the market.
India's drug regulators are intensifying GLP-1 oversight ahead of semaglutide's patent expiry. The Drug Controller General audited 49 entities and issued notices to violators.
India's Central Drugs Standard Control Organization issued advisories against unsupervised use of semaglutide and tirzepatide for weight loss, cracking down on misleading social media promotions and unapproved compounded versions.
Novo Nordisk cut Ozempic prices 36% and Wegovy 48% in India as generic semaglutide from Dr Reddy's, Sun Pharma, and Zydus entered the market with prices as low as Rs 1,290/month.
Analysts expect Novo's aggressive cuts to capture the lion's share of India's GLP-1 market in 12-18 months. Eli Lilly's Mounjaro currently dominates with ~79% share vs Novo's ~21%.
Following Novo Nordisk's patent expiry on March 20, more than 50 generic semaglutide versions are anticipated in India, dramatically expanding GLP-1 access.
Dr. Reddy's will rename its semaglutide drug from 'Olymviq' to 'Olymra' after Delhi High Court flagged similarity to Novo Nordisk's 'Ozempic'. Fierce competition in India's generic market.
Biocon's incoming CEO said the company will prioritize Canada, Brazil, and the Middle East instead of India's saturated GLP-1 market with 40+ generic entrants.